George Clinical Appoints Mary Gunn As New Chief Executive Officer

George Clinical is pleased to confirm the appointment of Mary Gunn as its new Chief Executive Officer. As a global executive, Mary brings to the role extensive experience in high-growth life sciences, financial services, and the education sectors. Mary will also be a director on the Board.

Mary Gunn succeeds James Cheong who has served as CEO for five and a half years

The Board of George Clinical extends its gratitude to James for his dedication and significant contributions to the company over this time.


Bio

With over three decades of experience, Dr Gunn has held pivotal roles in leading biotech firms and academic institutions including Pfizer, Crucell (Johnson & Johnson), Becton Dickson, Clintec (IQVIA), ICON, and Health Decisions (Premier Research).

She is a corporate strategy expert with extensive experience in life science corporate development, strategic partnerships, co-development, licensing partnerships, M&A and post-merger integrations.

She is renowned for her extensive contributions to medical research, innovative drug development, contract research and clinical trials, and has spearheaded the development of several FDA-approved drugs, particularly in the CNS and vaccines domains. She is passionate about market access to innovation.

Share